Academic Experience
· 1996 : Bachelor of Science in Medicine, Seoul National University College of Medicine (MD)
· 1998 : Master of Science in Medicine, Seoul National University College of Medicine ((MS)
· 2000 : Doctor of Philosophy in Medicine, Seoul National University College of Medicine (PhD)
· 2001~2004 : Postdoctoral Fellow, Seoul National University College of Medicine (Postdoc)
· 2004~ 2008 : Assistant Professor, College of Pharmacy, Seoul National University
·2008~ 2014 : Associate Professor, College of Pharmacy, Seoul National University
·2008~ Present : Professor, College of Pharmacy, Seoul National University
·2013~ 2016 : Director, Research Center for Personalized Cancer Medicine
·2016~ Present : Professor, Department of Molecular Medicine Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University
·2019~ 2024 : Dean, Department of Molecular Medicine Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University
·2020~ Present : Director, Startup Support Program for Biotechnology, Strategic Planning Division, Seoul National University Siheung Campus
·2024~ Present : Director, Siheung Campus and Director of the Future Innovation Research Institute, Seoul National University
Entrepreneurial Experience
· 2010~ Present : Founder & CEO of Abion
· 2016~ Present : Founder & Board Member, ROGONE Bio Research Convergence Center
Achievements & Awards
[Patents]
· Registration: Domestic : 33 cases, Overseas : 96cases
· Application: Domestic : 23 cases, Overseas : 74 cases
[Articles]
· 189 papers
[Technology transfer and commercialization]
· Technology transfer: 11 cases
– Technologies to build a platform for IUO providers supporting companion diagnostics
– Technologies needed to develop NGS-based companion diagnostic tests from projects within an oncology companion diagnostics consortium
– A method for predicting prognosis in breast cancer patients by analyzing gene deletions
– A composition for treating cancers associated with HPV infection
– Gene markers for predicting early breast cancer prognosis and their applications, etc
· Commercialization: 3 cases
– Development of diagnostic tool for non-small cell lung cancer : GenesWellTMddEGFR Mutation Test , GenesWellTM DX BCT
– Circulating tumor cell isolation technology : GenoCTC I, GenoCTC II
– In vitro molecular diagnostics (IVD) : Lung Acute Test
[Awards]
– Lee Eun-bang Prize for Outstanding Achievements in New Drug Development (26, Oct., 2023)